CO6321226A2 - Composiciones de ketorolac trometamina para tratar o prevenir el dolor ocular - Google Patents

Composiciones de ketorolac trometamina para tratar o prevenir el dolor ocular

Info

Publication number
CO6321226A2
CO6321226A2 CO10121549A CO10121549A CO6321226A2 CO 6321226 A2 CO6321226 A2 CO 6321226A2 CO 10121549 A CO10121549 A CO 10121549A CO 10121549 A CO10121549 A CO 10121549A CO 6321226 A2 CO6321226 A2 CO 6321226A2
Authority
CO
Colombia
Prior art keywords
ketorolac
thrometamine
treat
compositions
eye pain
Prior art date
Application number
CO10121549A
Other languages
English (en)
Inventor
Eldon Quinn Farnes
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40852460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6321226(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CO6321226A2 publication Critical patent/CO6321226A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

1.- Una solución oftálmica tópica acuosa que comprende keterolac trometamina, carboximetilcelulosa y ningún preservante.2.- La solución oftálmica acuosa tópica de la reivindicación 1 en donde la ketorolac trometamina está presente en una concentración de aproximadamente 0.40 - 0.45 por ciento en peso/volumen.3.- La solución oftálmica acuosa tópica de la reivindicación 1 en donde la carboximetilcelulosa es una combinación de carboximetilcelulosa de media y alta viscosidad.4.- La solución oftálmica acuosa tópica de la reivindicación 1 en donde la ketorolac trometamina está presente en una concentración de 0.45 por ciento en peso/volumen.5.- La solución oftálmica acuosa tópica de la reivindicación 4 que tiene un pH entre 6.8 y 7.4.6.- La solución oftálmica acuosa tópica de la reivindicación 5 en donde la concentración de carboximetilcelulosa es desde 0.2 a 2 por ciento en peso.7.- La solución oftálmica acuosa tópica de la reivindicación 5 que tiene un pH de aproximadamente 6.8.8.- La solución acuosa tópica de la reivindicación 4 en donde la solución está libre de tensioactivo y secuestrante.
CO10121549A 2008-03-03 2010-09-30 Composiciones de ketorolac trometamina para tratar o prevenir el dolor ocular CO6321226A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6792508P 2008-03-03 2008-03-03
US9609608P 2008-09-11 2008-09-11
US11191908P 2008-11-06 2008-11-06
US12/396,131 US7842714B2 (en) 2008-03-03 2009-03-02 Ketorolac tromethamine compositions for treating ocular pain

Publications (1)

Publication Number Publication Date
CO6321226A2 true CO6321226A2 (es) 2011-09-20

Family

ID=40852460

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10121549A CO6321226A2 (es) 2008-03-03 2010-09-30 Composiciones de ketorolac trometamina para tratar o prevenir el dolor ocular

Country Status (21)

Country Link
US (8) US7842714B2 (es)
EP (2) EP2257275B1 (es)
JP (1) JP5705552B2 (es)
KR (1) KR101560429B1 (es)
CN (1) CN102014869A (es)
AT (1) ATE538775T1 (es)
AU (1) AU2009222016B2 (es)
BR (1) BRPI0909100B1 (es)
CA (1) CA2717520C (es)
CO (1) CO6321226A2 (es)
DK (2) DK2446878T3 (es)
ES (2) ES2382509T3 (es)
HK (1) HK1149212A1 (es)
HU (1) HUE027102T2 (es)
IL (1) IL207925A (es)
MX (1) MX2010009763A (es)
MY (1) MY150250A (es)
NZ (2) NZ602445A (es)
PL (2) PL2446878T3 (es)
WO (1) WO2009111418A2 (es)
ZA (1) ZA201006372B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332049T5 (es) * 2003-08-07 2014-03-27 Allergan, Inc. Composiciones de administración de sustancias terapéuticas en los ojos
US9192571B2 (en) 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
SI2555770T1 (en) * 2010-04-09 2018-04-30 Allergan, Inc. Creation of ketorolac for the treatment of corneal damage
US9138481B2 (en) 2011-12-06 2015-09-22 Alcon Research, Ltd. Cellulosic gel composition with improved viscosity stability
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
DE102013006596A1 (de) * 2013-04-17 2014-10-23 Jaime Guardiola Verfahren zum Herstellen einer sterilen intraokularen Spül-Lösung und Spül-Lösung
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150335704A1 (en) 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
WO2018031973A1 (en) 2016-08-12 2018-02-15 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
US20200170998A1 (en) * 2018-11-29 2020-06-04 Cellula Llc Umbilical cord blood serum and umbilical cord blood plasma preparation in combination with a nonsteroidal anti-inflammatory drug and freeze-drying the composition

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
DE1544943A1 (de) * 1964-02-12 1969-07-31 Goodrich Co B F Waermehaertbare Vinylplastisole
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4021416A (en) * 1975-05-05 1977-05-03 Polaroid Corporation Thiol polymers
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4474787A (en) 1977-05-04 1984-10-02 Fisons Limited 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
DE3125636A1 (de) * 1981-06-30 1983-01-13 Merck Patent Gmbh, 6100 Darmstadt 1-(p-2-isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol zur senkung des augeninnendrucks und ophtalmikum, enthalten diese verbindung
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US6255299B1 (en) 1985-01-07 2001-07-03 Leo Pharmaceutical Products Ltd. Opthalmic gel composition and method of treating eye infections
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5414011A (en) 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US5110493A (en) 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US6174999B1 (en) 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5017229A (en) 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5527893A (en) 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US4861514A (en) 1988-06-08 1989-08-29 The Drackett Company Compositions containing chlorine dioxide and their preparation
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
CA2063576C (en) * 1989-06-07 1994-01-25 Gail S. Bazzano Slow release vehicles for minimizing skin irritancy of topical compositions
US5045121A (en) * 1989-06-21 1991-09-03 Gte Products Corporation Method for removing carbon from cemented tungsten carbide articles
US5112822A (en) 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
IT1250691B (it) 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
US5460834A (en) 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
WO1993017664A1 (en) 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU666957B2 (en) 1992-08-28 1996-02-29 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US5648074A (en) 1993-05-25 1997-07-15 Allergan Compositions and methods for disinfecting contact lenses and reducing proteinaceous deposit formation
ES2187533T3 (es) 1993-10-13 2003-06-16 Allergan Inc Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina.
US6294202B1 (en) 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5807541A (en) * 1996-04-22 1998-09-15 Sepracor, Inc. NSAID/fluoride periodontal compositions and methods
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US5858346A (en) 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
JP2002539157A (ja) 1999-03-15 2002-11-19 トラスティーズ オブ ボストン ユニバーシティ 血管新生阻害
JP2002541682A (ja) * 1999-04-08 2002-12-03 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ パンチスルーダイオード及び同ダイオードを製造する方法
ITMI991453A1 (it) 1999-07-01 2001-01-01 Farmila Farma Milano Composizioni oftalmiche in forma di gel acquosi
US7141607B1 (en) * 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
CA2402405C (en) * 2000-07-14 2008-02-12 Allergan Sales, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20020198210A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
US8008338B2 (en) * 2003-06-03 2011-08-30 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
ES2332049T5 (es) * 2003-08-07 2014-03-27 Allergan, Inc. Composiciones de administración de sustancias terapéuticas en los ojos
WO2005101982A2 (en) 2004-03-24 2005-11-03 Sun Pharmaceutical Industries Limited A stable ophthalmic composition
ZA200704869B (en) 2004-12-23 2009-02-25 Roxro Pharma Inc Therapeutic compositions for intranasal administration of ketorolac
US20070254841A1 (en) * 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
US20070299124A1 (en) * 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
US20080039398A1 (en) 2006-01-25 2008-02-14 Ousler George W Iii Formulations and methods for treating dry eye
US20070287741A1 (en) 2006-06-13 2007-12-13 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
CN101754748A (zh) 2007-05-24 2010-06-23 阿西克斯医疗公司 治疗干眼症的制剂和方法
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
ES2399314T3 (es) * 2008-04-24 2013-03-27 Allergan, Inc. Gamma lactamas sustituidas como agentes terapeúticos
US20080275118A1 (en) * 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss

Also Published As

Publication number Publication date
EP2446878A1 (en) 2012-05-02
US20230181497A1 (en) 2023-06-15
JP2011513416A (ja) 2011-04-28
NZ602445A (en) 2014-06-27
PL2257275T3 (pl) 2012-05-31
DK2446878T3 (en) 2016-04-04
HUE027102T2 (en) 2016-08-29
KR101560429B1 (ko) 2015-10-15
ES2382509T3 (es) 2012-06-08
BRPI0909100B1 (pt) 2019-01-15
CN102014869A (zh) 2011-04-13
US20110160271A1 (en) 2011-06-30
MY150250A (en) 2013-12-31
US20090326034A1 (en) 2009-12-31
WO2009111418A3 (en) 2010-04-01
EP2446878B1 (en) 2015-12-30
PL2446878T3 (pl) 2016-06-30
CA2717520C (en) 2012-05-01
CA2717520A1 (en) 2009-09-11
MX2010009763A (es) 2010-12-07
US20110046198A1 (en) 2011-02-24
EP2257275B1 (en) 2011-12-28
US7842714B2 (en) 2010-11-30
JP5705552B2 (ja) 2015-04-22
IL207925A (en) 2015-03-31
KR20100130989A (ko) 2010-12-14
NZ588367A (en) 2013-03-28
HK1149212A1 (en) 2011-09-30
US20200197336A1 (en) 2020-06-25
ATE538775T1 (de) 2012-01-15
US20120196913A1 (en) 2012-08-02
AU2009222016A1 (en) 2009-09-11
BRPI0909100A2 (pt) 2015-08-11
ES2566162T3 (es) 2016-04-11
ZA201006372B (en) 2011-05-25
IL207925A0 (en) 2010-12-30
WO2009111418A2 (en) 2009-09-11
US20120196914A1 (en) 2012-08-02
US20110275688A1 (en) 2011-11-10
DK2257275T3 (da) 2012-04-02
AU2009222016B2 (en) 2014-09-04
EP2257275A2 (en) 2010-12-08

Similar Documents

Publication Publication Date Title
CO6321226A2 (es) Composiciones de ketorolac trometamina para tratar o prevenir el dolor ocular
EP2424360A4 (en) TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
BRPI0920137A2 (pt) implante ocular
MY171920A (en) Prevention and treatment of ocular conditions
UY30663A1 (es) Dihidropirazolonas sustituidas y su uso
BRPI0710085B8 (pt) composições oftálmicas e seus kits
ES2964952T3 (es) Prótesis escleral para el tratamiento de la presbicia y otros trastornos oculares
BR112012010261A2 (pt) dispositivo de microcânula, e, métodos para tratar o espaço supracoroidal de um olho, para tratar a região posterior de um olho e para tratar os tecidos dentro ou adjacentes ao espaço supracoroidal de um olho
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
BRPI0812755A2 (pt) Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
GT200600277A (es) Derivados de prostaglandina
UY32758A (es) Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BRPI0819105A2 (pt) composição para o tratamento e prevenção de edema de pálpebra
EA201201239A1 (ru) Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
UY33153A (es) Formulación tópica oftálmica de péptidos
CL2015002188A1 (es) Agentes analgésicos oculares tópicos
HN2007000505A (es) Analogos de pirazol
UY33562A (es) Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma
WO2010031096A8 (de) Antimikrobiell und antiviral wirkende zusammensetzung
BRPI0915085A2 (pt) métodos para reduzir o teor de um composto e a oxidação no tecido ocular, e, método para melhorar o desempenho visual de um indivíduo
BRPI0923502A2 (pt) composições de soluções oculares tópicas para fornecer concentrações eficiêntes de agente ativo no segmento posterior do olho

Legal Events

Date Code Title Description
FC Application refused